Try our beta test site
279 studies found for:    Open Studies | Bladder cancer
Show Display Options
Rank Status Study
1 Recruiting Biomarker Identification for Bladder Cancer Patients
Condition: Bladder Cancer
Intervention: Procedure: Sample Collection
2 Recruiting Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Pembrolizumab;   Drug: Cisplatin;   Radiation: Radiotherapy
3 Recruiting Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: cisplatin;   Drug: fluorouracil;   Drug: mitomycin C
4 Recruiting Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Celecoxib;   Drug: Gemcitabine;   Drug: Cisplatin
5 Recruiting Enzalutamide for Bladder Cancer Chemoprevention
Condition: Bladder Cancer
Intervention: Drug: Enzalutamide
6 Recruiting VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: VPM1002BC
7 Not yet recruiting Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Mitomycin C;   Procedure: Surgical Management
8 Recruiting Metformin and Simvastatin Use in Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Metformin;   Drug: Simvastatin
9 Recruiting MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer
Condition: Bladder Cancer
Intervention: Device: MR imaging
10 Recruiting A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Condition: Bladder Cancer
Interventions: Drug: Hexaminolevulinate hydrochloride;   Device: KARL STORZ D-Light C PDD Flexible Videoscope System
11 Recruiting MK-3475/BCG in High Risk Superficial Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Intravenous MK-3475/ Intravesical BCG
12 Recruiting PET/MRI and Biomarkers in Bladder Cancer
Condition: Bladder Cancer
Intervention: Device: MRI/acetate-PET imaging
13 Recruiting Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Condition: Bladder Cancer
Interventions: Procedure: white light TUR-BT;   Procedure: blue light TUR-BT;   Drug: optimized MMC;   Drug: single immediate chemotherapy instillation
14 Recruiting Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Condition: Bladder Cancer
Intervention: Drug: Tamoxifen Citrate
15 Recruiting Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
Condition: Bladder Cancer
Interventions: Procedure: Tissue Biopsy;   Procedure: Magnetic Resonance Imaging (MRI)
16 Recruiting Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)
Condition: Bladder Cancer
Interventions: Device: HoLERBT;   Device: cTURBT
17 Recruiting S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Methotrexate;   Drug: Vinblastine;   Drug: Doxorubicin;   Drug: Filgrastim
18 Recruiting Detecting Bladder Cancer Using the UroMark Test.
Condition: Bladder Cancer
Intervention: Other: Group
19 Not yet recruiting Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
Condition: Bladder Cancer
Interventions: Drug: Vinflunine;   Drug: Cisplatin;   Procedure: Radical cystectomy
20 Recruiting Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Condition: Bladder Cancer
Interventions: Other: Immediate Surgery;   Other: Observation;   Procedure: Surveillance Cystoscopy and Urinary Cytology

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.